A double-blind, placebo-controlled study of memantine in the treatment of major depression
A double-blind, placebo-controlled study of memantine in the treatment of major depression
复制标题
DOI：
10.1176/appi.ajp.163.1.153
复制
发表时间：
2006-01-01
影响因子：
17.7
通讯作者：
Charney, DS
中科院分区：
文献类型：
--
作者：
Zarate, CA;Singh, JB;Charney, DS
目的：方法：采用双盲、安慰剂对照的方法，将32例抑郁症患者随机分为两组，每组16例，分别服用美金刚（5-20 mg/d）和安慰剂，疗程8周。主要疗效进行了评估的Montgomery-Asberg抑郁量表（MADRS.Results）上的性能：总MADRS评分的线性混合模型显示没有治疗effect.Conclusions：在一个为期8周的试验中，低到中等亲和力的NMDA拮抗剂美金刚胺的剂量为5-20毫克/天是没有有效的治疗抑郁症。
Objective: This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate ( NMDA) receptor antagonist in humans.Method: In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N = 16) or placebo (N = 16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).Results: The linear mixed models for total MADRS scores showed no treatment effect.Conclusions: In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.